Kyowa Kirin Will Present New Rocatinlimab Phase 2b Data in Atopic Dermatitis at the American Academy of Dermatology Annual Meeting 2023
- Friday, March 17, 2023, 7:11
- Business
- Add a comment
BEDMINSTER, N.J. and TOKYO, March 17, 2023 /PRNewswire/ — Kyowa Kirin Co., Ltd. (TSE: 4151) today announces that data from the Phase 2b study of rocatinlimab (KHK4083/AMG 451), an investigational product in patients with moderate-to-severe atopic dermatitis, will be presented in two…
About the Author
adminasapcorp has written 41802 stories on this site.